Iovance Biotherapeutics IncNASDAQ:IOVA
- LAST PRICE7.9950
- TODAY'S CHANGE (%)-0.1650 (-2.0221%)
- Bid / Lots7.9900/ 4
- Ask / Lots8.0000/ 10
- Open / Previous Close8.0500 / 8.1600
- Day Range
- 52 Week Range
- Volume498,682
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IOVA |
|---|---|---|
| 09:32 ET | 81270 | 8.17 |
| 09:33 ET | 16681 | 8.15 |
| 09:35 ET | 23876 | 8.06 |
| 09:37 ET | 3755 | 8.09 |
| 09:39 ET | 30430 | 8.045 |
| 09:42 ET | 39633 | 7.9877 |
| 09:44 ET | 24047 | 8 |
| 09:46 ET | 18387 | 8.0425 |
| 09:48 ET | 15961 | 8.07 |
| 09:50 ET | 18054 | 8.05 |
| 09:51 ET | 21008 | 7.99 |
| 09:53 ET | 12778 | 8.01 |
| 09:55 ET | 17786 | 8 |
| 09:57 ET | 19495 | 8 |
| 10:00 ET | 9112 | 7.9987 |
| 10:02 ET | 25960 | 7.99 |
| 10:04 ET | 14280 | 7.97 |
| 10:06 ET | 40259 | 8.01 |
| 10:08 ET | 8096 | 7.995 |
| 10:09 ET | 3232 | 7.995 |
Jan 27, 2023
Piper Sandler Upgrades Iovance Biotherapeutics to Overweight From Neutral, Adjusts Price Target to $14 From $11, from 9:40AM ET on Friday Jan 27, 2023 by MT Newswires
9:40AM ET on Friday Jan 27, 2023 by MT Newswires
Jan 24, 2023
Truist Securities Adjusts Iovance Biotherapeutics' Price Target to $17 From $16, Keeps Buy Rating, from 10:25AM ET on Tuesday Jan 24, 2023 by MT Newswires
10:25AM ET on Tuesday Jan 24, 2023 by MT Newswires
Jan 23, 2023
BRIEF-Iovance Biotherapeutics Provides Corporate, Clinical, And Regulatory Updates, from 8:13AM ET on Monday Jan 23, 2023 by Thomson Reuters
8:13AM ET on Monday Jan 23, 2023 by Thomson ReutersBRIEF-Clinigen Divests Proleukin® To Iovance Biotherapeutics For £166.7 Million, from 8:11AM ET on Monday Jan 23, 2023 by Thomson Reuters
8:11AM ET on Monday Jan 23, 2023 by Thomson ReutersClinigen divests Proleukin(R) to Iovance Biotherapeutics for £166.7 million, from 8:06AM ET on Monday Jan 23, 2023 by GlobeNewswire
8:06AM ET on Monday Jan 23, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Iovance Biotherapeutics Inc | 1.3B | -3.2x | --- |
Geron Corp | 1.3B | -9.3x | --- |
CinCor Pharma Inc | 1.3B | -12.2x | --- |
NewAmsterdam Pharma Company NV | 1.3B | -78.4x | --- |
Zentalis Pharmaceuticals Inc | 1.3B | -5.0x | --- |
Cassava Sciences Inc | 1.2B | -15.9x | --- |
Company Information
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. It has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer, as well as LN-145 for metastatic non-small cell lung cancer (NSCLC). In addition, the Company is investigating the combinations of TIL therapy with immune checkpoint inhibitors (ICIs) in metastatic melanoma, cervical cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). It is investigating peripheral blood lymphocyte (PBL) therapy for patients with refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Contact Information
- Headquarters
- 825 INDUSTRIAL ROAD, 4TH FLOORSAN CARLOS, CA, United States 94070
- Phone
- 650-260-7120
- Fax
- 302-697-4597
Executives
- Chairman of the Board
- Iain Dukes
- Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
- Frederick Vogt
- Chief Financial Officer
- Jean-Marc Bellemin
- Chief Operating Officer
- Igor Bilinsky
- Chief Medical Officer
- Friedrich Graf Finckenstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 157.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.20 |
EPS | $-2.48 |
Book Value | $3.96 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
